research Potassium channel openers: therapeutic potential in cardiology and medicine
Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
Search
for
Sort by
Research
600-630 / 1000+ results 
research 976 Knockout of mTOR/Akt inhibitor REDD1 results in hair cycle-independent dermal adipose expansion by promoting adipocyte differentiation
Removing REDD1 in mice increases skin fat by making fat cells larger and more numerous.
research Prescribers alerted to potential adverse effects of finasteride and montelukast
research Oleic Acid Nanovesicles of Minoxidil for Enhanced Follicular Delivery
Oleic acid nanovesicles improve minoxidil absorption in hair follicles for alopecia treatment.
research Albendazole treatment of echinococcosis in humans: Effects on microsomal metabolism and drug tolerance
Albendazole treatment for echinococcosis can cause serious side effects and requires close monitoring.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
research Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
research Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth
Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research Valproic acid and/or rapamycin preconditioning protects hair follicle stem cells from oxygen glucose serum deprivation-induced oxidative injury via activating Nrf2 pathway.
Valproic acid and rapamycin protect hair follicle stem cells from damage by activating a protective pathway.
research Pharmacokinetics of Finasteride in the Elderly Volunteers.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Review of Promising Off-Label Use of Deucravacitinib
Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
research Ann Robinson’s research reviews —12 May 2022
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
research Alfatradiol (0,025 %) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern
Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
research 549 Temporary cell cycle arrest in human scalp hair follicles and their epithelial stem cells by ALRN-6924: A novel strategy to selectively protect p53-wildtype cells against paclitaxel-induced alopecia
ALRN-6924 may prevent hair loss caused by chemotherapy.
research Medium-dose prednisolone pulse therapy in alopecia areata
Medium-dose prednisolone pulse therapy is effective and safe for multifocal alopecia areata but not for more severe forms.
research [Mycophenolate mofetil in induction and maintenance therapy for juvenile onset severe lupus nephritis].
Mycophenolate mofetil is effective for treating severe lupus nephritis in children.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research ISID1077 – Efficacy and safety of ENERGI-F701 solution versus 2% minoxidil solution for female pattern hair loss: a phase II, multi-center, randomized, double-blind, head-to-head, parallel trial
research Effect of cyclosporin, minoxdile. Testosterone, estradiol and corticosteroid on hair growth of nude mice
Cyclosporin and minoxidil promote hair growth.
research Alopecia areata: Time for position statement to include new systemic therapeutic advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
research VP-16-213 (etoposide): The mandrake root from Issyk-Kul
Etoposide is effective in treating several cancers, especially small cell lung cancer, with acceptable side effects.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Change of Vascular Endothelial Growth Factor resulted by different Minoxidil praeparatums in C57BL/6 Mouse
Lipo-minoxidil increases VEGF expression more than regular minoxidil.
research Delayed Onset of Alopecia Areata in a Patient on Ocrelizumab for Multiple Sclerosis: A Case Report
Ocrelizumab may cause delayed hair loss in some patients.
research Effect of minoxidil combined with triamcinolone acetonide on alopecia areata by microneedle injection
Minoxidil with triamcinolone acetonide is more effective for mild alopecia areata when injected with microneedles than when applied topically.
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.